| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/16/2005 | US6930122 Use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3 -carboxamide, a salt thereof or a solvate thereof |
| 08/16/2005 | US6930115 Antitumor effect potentiators |
| 08/16/2005 | US6930112 Administering antagonist for n-methylaspartic acid or gamma-aminobutyric acid |
| 08/16/2005 | US6930106 Inhibitors of HCV NS5B polymerase |
| 08/16/2005 | US6930090 Methods of activating a receptor using amphiphilic drug-oligomer conjugates |
| 08/16/2005 | US6929955 Interactive system for presenting and eliminating substances |
| 08/16/2005 | US6929954 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 08/16/2005 | US6929818 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/16/2005 | US6929805 For oral administration comprising an analgesic with rapid onset of action and at least one systemically acting analgesic with sustained action, such as a combination of benzocaine and acetylsalicylic acid (ASA) |
| 08/16/2005 | US6929802 Method of cancer treatment |
| 08/16/2005 | US6929800 Nasal passage cleaning composition |
| 08/11/2005 | WO2005073395A1 Method of examining ability to regulate the expression of neprilysin activity |
| 08/11/2005 | WO2005072893A1 Functionalized colloidal metal compositions and methods |
| 08/11/2005 | WO2005072774A1 Vaginal compositions for treating infections |
| 08/11/2005 | WO2005072773A1 Erythrocyte function modifying substance |
| 08/11/2005 | WO2005072771A1 Neuroprotective complex for treatment of cerebral ischemia and injury |
| 08/11/2005 | WO2005072767A1 Agent for improving sugar metaboic function |
| 08/11/2005 | WO2005072764A2 Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells |
| 08/11/2005 | WO2005072751A1 Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis |
| 08/11/2005 | WO2005072748A1 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis |
| 08/11/2005 | WO2005072740A2 Anorectic compounds |
| 08/11/2005 | WO2005072705A1 Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| 08/11/2005 | WO2005072343A2 Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use |
| 08/11/2005 | WO2005072268A2 Treatment of degeneraative cartilage conditions in a mammal with glycosidase inhibitors |
| 08/11/2005 | WO2005072113A2 Compositions and methods of treatment for inflammatory diseases |
| 08/11/2005 | WO2005062791A3 Utilization of stem cell and fibroblast combined products and nutrients in topical compositions |
| 08/11/2005 | WO2005057588A3 Granulated decontamination formulations |
| 08/11/2005 | WO2005049058A8 Radix salviae miltiorrhizae, extract and composition thereof for the treatment of the aspirin resistance diseases |
| 08/11/2005 | WO2005046617A3 Compositions and methods for reducing microbial induced apoptosis |
| 08/11/2005 | WO2005039639A3 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| 08/11/2005 | WO2005037245A3 A multiple route medication for the treatment of rhinitis and asthma |
| 08/11/2005 | WO2005034998A3 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 08/11/2005 | WO2005034908A3 A solid dosage form comprising a fibrate and a statin |
| 08/11/2005 | WO2005020897A3 Compositions and methods for the treatment of disease associated with trp-p8 expression |
| 08/11/2005 | WO2005011651A3 Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| 08/11/2005 | WO2005000283A3 A method of treating degenerative disc disease |
| 08/11/2005 | WO2004112837A8 PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND INTERLEUKIN-1α PRODUCTION INHIBITOR |
| 08/11/2005 | US20050177881 Using presence of allelic mutations in lysosomal acid lipase (LIPA) and cholesterol 25-hydroxylase (CH25H) as diagnostic indicator of nervous system disorders |
| 08/11/2005 | US20050177876 Fcyriia transgenic animal model for autoimmune disease |
| 08/11/2005 | US20050176955 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as hiv integrase inhibitors |
| 08/11/2005 | US20050176944 Intracellular signaling polypeptide for identifying modulator for prevention and treatment cell proliferative, endocrine, autoimmune/inflammatory, neurological, gastrointestinal, reproductive, developmental, and vesicle trafficking disorders |
| 08/11/2005 | US20050176931 Eotaxin : eosinophil chemotactic cytokine |
| 08/11/2005 | US20050176930 Nucleotide sequences coding tumor associated antigen for use in diagnosis, prevention and treatment of cell proliferative disorders; mimetics; antitumor agents |
| 08/11/2005 | US20050176927 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; diagnosis |
| 08/11/2005 | US20050176826 Use of asc-1 inhibitors to treat neurological and psychiatric disorders |
| 08/11/2005 | US20050176823 Intra-operative procedure for post-operative pain control |
| 08/11/2005 | US20050176820 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| 08/11/2005 | US20050176809 Method and compositions for treatment of painful disorders |
| 08/11/2005 | US20050176806 Use of 1-[3-hydroxy-1-adamantylamino]acetyl-2-cyano-pyrrolidine, for example with other anticholesterol drugs such as statins |
| 08/11/2005 | US20050176800 Preterm labor, dysmenorrhea, asthma, hypertension, fertility disorder, sexual dysfunction, undesired blood clotting, bone disorders, preeclampsia or eclampsia, or an eosinophil disorder; use with phosphodiesterase inhibitors; e.g. 7-[(2R,3R)-3-Chloro-1-(4-hydroxynonyl)-pyrrolidin-2-yl]-hept-5-enoic acid |
| 08/11/2005 | US20050176796 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 08/11/2005 | US20050176765 For therapy of glaucoma, dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia; -[1-[1-(3-Thienoyl)piperidin-4-yl]piperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one |
| 08/11/2005 | US20050176746 Treating eating disorders and digestive disorders wth loperamide |
| 08/11/2005 | US20050176740 Synergistic for cancer characterized by ras oncogene overexpression; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine |
| 08/11/2005 | US20050176737 Mitotic kinesin inhibitors |
| 08/11/2005 | US20050176725 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide; antitumor; antiproliferative agent; synergistic therapy for resistant; Bcr/Abl, leukemia |
| 08/11/2005 | US20050176720 Pharmaceutical composition for the treatment of CNS and other disorders |
| 08/11/2005 | US20050176714 Pyridazine derivatives |
| 08/11/2005 | US20050176712 Integrin expression inhibitor |
| 08/11/2005 | US20050176703 Heterocyclic antiviral compounds |
| 08/11/2005 | US20050176700 (2-methoxyphenyl)acetic acid-7-{4-[3-(2-methoxybenzyloxy)-propoxy]phenyl}-3-(2-thiophen-2-ylacetyl)-3,9-diazabicyclo[3.3.1]non-6-en-6-yl-methyl ester; metabolically stable, orally bioavailable and sufficiently soluble; industrial scale; non-peptidic nature, low molecular weight |
| 08/11/2005 | US20050176698 Neuropeptide Y antagonists |
| 08/11/2005 | US20050176691 Combination therapy for the treatment of estrogen-sensitive disease |
| 08/11/2005 | US20050176687 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 08/11/2005 | US20050176685 Administering bisphosphonate compounds such as ibandronate, minodronate, pamidronate, risedronate, zoledronate, and alendronate; osteoporosis |
| 08/11/2005 | US20050176681 Immunomodulators; side effect reduction; non-Hodgkin's lymphoma, myelogenous leukemia, amyloidosis, and cancer of ovaries, pancreas, kidneys |
| 08/11/2005 | US20050176680 Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 08/11/2005 | US20050176678 Compounds and method for coating surfaces in a haemocompatibe manner |
| 08/11/2005 | US20050176674 Administering sulfur containing amino acid and manganese |
| 08/11/2005 | US20050176661 Antiviral oligonucleotides |
| 08/11/2005 | US20050176648 oligopeptide including enantiomers, stereoisomers and tautomers, used as hepatitis c protease enzyme inhibitors for prophylaxis or prevention of viral diseases |
| 08/11/2005 | US20050176639 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 08/11/2005 | US20050176630 Modification of feeding behavior |
| 08/11/2005 | US20050176077 Using urease as tool in identifying modulators of bacterial propagation; enzyme inhibitors |
| 08/11/2005 | US20050176060 Crystal structure |
| 08/11/2005 | US20050176044 Polynucleotides and polypeptides encoding receptors |
| 08/11/2005 | US20050176024 chemically synthesized double stranded siNA that directs cleavage of EGFR such as HER1, HER2, HER3 or HER4; diagnosis or treatment of cancer for example |
| 08/11/2005 | US20050176013 Identifying modulators of 3'-phosphoadenosine 5'-phosphosulfate synthase 1(PAPPS-1) activity; antitumor agents; tumor diagnostics |
| 08/11/2005 | US20050176004 Rheumatoid arthritis disease sensitive gene, its protein, method and kit of judging the onset of rheumatoid arthritis using the same, and method and drugs for treating rheumatoid arthritis |
| 08/11/2005 | US20050175998 Immunoconjugate for stimulating myelinogenesis, differentiation of oligodendroglial precursor cells, tyrosine kinase, the expression of myelin basic protein and detecting myelinogenetic oligodendroglias |
| 08/11/2005 | US20050175724 Composition for modulating at least one physiological reaction or inducing an immune response in human or animal after oral administration; for intestinal delivery of a physiologically active agent, a neutralizing agent, an inhibitor of digestive enzymes, an uptake increasing agent; synergistic |
| 08/11/2005 | US20050175692 Pharmaceutical formulation comprising melatonin |
| 08/11/2005 | US20050175647 Compositions for topical application having androgenic actions |
| 08/11/2005 | US20050175639 Methods |
| 08/11/2005 | US20050175637 Methods for enhancing wound healing |
| 08/11/2005 | US20050175629 Helicobacter pylori vaccination |
| 08/11/2005 | US20050175613 Compositions and methods for treating hyperimmune response in the eye |
| 08/11/2005 | US20050175598 Methods of use of probiotic bifidobacteria for companion animals |
| 08/11/2005 | US20050175595 Method for reinstalling control system for antigenic homeostasis of mammalian organisms (effect of Kukharchuk-Radchenko-Sirman) |
| 08/11/2005 | US20050175584 Functionalized colloidal metal compositions and methods |
| 08/11/2005 | US20050175583 Making vector compositions that mimic the functionality of components of the immune system especially antigen-presenting cell (APC) element of the immune synapse; vaccination |
| 08/11/2005 | US20050175580 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| 08/11/2005 | US20050175565 Use of taurine for the treatment of alopecia |
| 08/11/2005 | US20050175549 Novel combination of anticholinergic and ss mimetics for the treatment of respiratory diseases |
| 08/11/2005 | US20050175548 a mixture of glycopyrrolate and budesonide, fluticasone, ciclesonide, mometasone, flunisolide, beclometason or loteprednol, used for treating respiratory system diosders and allergies; side effect reduction |
| 08/11/2005 | US20050175547 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 08/11/2005 | DE102004063612A1 Gel former, useful for making salt-containing products for mineral supplementation and deacidification in humans or animals, comprises at least two different natural polymers |
| 08/11/2005 | CA2609888A1 Polyphenols as an intravesical agent for the prevention of transitional cell tumor implantation |
| 08/11/2005 | CA2554959A1 Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| 08/11/2005 | CA2554755A1 Functionalized colloidal metal compositions and methods |